Skip to main contentSkip to navigation
Sirius Investors
Statera Biopharma, Inc.

Statera Biopharma, Inc.

STAB
OTCHealthcare

STAB Earnings Reports, EPS & Revenue History

Quarterly EPS and revenue vs. estimates for Statera Biopharma, Inc.. Review beat/miss history, upcoming consensus figures, and earnings call transcripts when available.

EPS and Earnings Announcement

Latest Quarterly EPS
Next Earnings Announcement
Unlock for free

Already registered? Sign in

EPS vs. Estimates

Green band = beat vs estimate · Red band = miss · Lines show actual and consensus EPS.

Revenue vs. Estimates

Green band = revenue beat · Red band = revenue miss · Lines show reported vs consensus revenue.

EPS & Revenue vs. Estimates

Upgrade
DateEPS ActualEPS Est.EPS Diff.Revenue ActualRevenue Est.Revenue Diff.
Jun 14, 2024
1.34670.47K
May 17, 2024
1.58670.47K
Feb 12, 2024
2.09670.47K
Dec 1, 2023
Aug 31, 2023
Aug 8, 2023
May 4, 2023
Nov 14, 2022
Nov 15, 2021
Aug 16, 2021
May 14, 2021
Mar 22, 2021
Nov 16, 2020
Aug 14, 2020
May 15, 2020
Nov 14, 2019
Aug 14, 2019
May 15, 2019
Nov 14, 2018
Aug 14, 2018
May 15, 2018
Mar 6, 2018
Nov 14, 2017
Aug 14, 2017
May 15, 2017
Feb 22, 2017
Nov 14, 2016
Aug 15, 2016
May 16, 2016
Nov 9, 2015
Aug 12, 2015
May 7, 2015
Nov 10, 2014
Aug 11, 2014
May 8, 2014
Mar 11, 2014
Nov 8, 2013
Aug 9, 2013
May 9, 2013
Mar 14, 2013
Nov 9, 2012
Aug 9, 2012
May 3, 2012
Mar 13, 2012
Nov 9, 2011
Aug 9, 2011
May 10, 2011
Mar 15, 2011
Nov 15, 2010
Aug 16, 2010
May 14, 2010
Mar 22, 2010
Nov 12, 2009
Aug 13, 2009
May 14, 2009
Mar 30, 2009
Nov 14, 2008
Aug 12, 2008
May 13, 2008
Mar 21, 2008
Nov 13, 2007
Aug 13, 2007
May 15, 2007
Nov 13, 2006
Aug 25, 2006

Earnings Call Transcripts

Upgrade

Earnings Call Transcripts Require Subscription

Access to earnings call transcripts and AI-powered summaries is available for Pro, Premium, and Enterprise subscribers.

View Pricing Plans

Revenue Breakdown

Want to understand STAB's revenue sources? Explore detailed revenue breakdowns by product line and geographic region to see what's driving the company's top line.

View Revenue Breakdown